B Cells and B Cell Depletion in Autoimmunity and Atherosclerosis
Jenny Lue Solomon, Anjali Dubbaka, Ankita Srivastava, Elise Belilos, Joshua De Leon, Steven E. Carsons, Allison B. Reiss · 2026
Read B Cells and B Cell Depletion in Autoimmunity and Atherosclerosis by Jenny Lue Solomon, Anjali Dubbaka, Ankita Srivastava, Elise Belilos, Joshua De Leon, Steven E. Carsons, Allison B. Reiss (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13300963.txt.
Description
Jenny Lue Solomon and co-authors review B cells and their depletion across autoimmunity and atherosclerosis in a 2026 article. B cells were once overshadowed by T cells in this field, yet they drive damage by making autoantibodies, presenting antigens, and releasing inflammatory signals. The review pairs two levers. The first is CD20 targeted drugs that wipe out B cells. The second is blockers of the neonatal Fc receptor, a recycling system that keeps harmful IgG antibodies alive far longer than they would otherwise last.
Each approach earns its place in rheumatologic and neurologic disease, and the authors weigh evidence for extending both into artery disease, where different B cell subsets can protect or harm. Combining depletion with faster antibody clearance could attack existing pathogenic IgG while stopping production at the source. Infection risk is the standing caution, and the authors call for careful trials before the combination becomes routine.
Catalog record
| CREATOR | Jenny Lue Solomon, Anjali Dubbaka, Ankita Srivastava, Elise Belilos, Joshua De Leon, Steven E. Carsons, Allison B. Reiss |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |